NCT00069316View on ClinicalTrials.gov

Omr-IgG-am(Trademark) for Treating Patients With or at High Risk for West Nile Virus Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

September 22, 2003

Primary Completion Date

June 27, 2007

Study Completion Date

June 27, 2007

Conditions
West Nile Virus
Interventions
DRUG

Omr-IgG-am

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Institutes of Health Clinical Center (CC)

NIH

NCT00069316 - Omr-IgG-am(Trademark) for Treating Patients With or at High Risk for West Nile Virus Disease | Biotech Hunter | Biotech Hunter